0
0

To amend section 503B of the Federal Food, Drug, and Cosmetic Act to enhance the ability of outsourcing facilities to mitigate drug shortages by allowing a short-term period to continue supplying the market after a drug is in shortage.

2/13/2026, 9:06 AM

Summary of Bill HR 7528

H.R. 7528 of the 119th Congress, introduced on February 12, 2026, aims to amend section 503B of the Federal Food, Drug, and Cosmetic Act to improve outsourcing facilities' capacity to address drug shortages. The bill proposes allowing a temporary period for these facilities to maintain market supply even after a drug has become scarce, with the goal of mitigating shortages effectively.

Current Status of Bill HR 7528

Bill HR 7528 is currently in the status of Bill Introduced since February 12, 2026. Bill HR 7528 was introduced during Congress 119 and was introduced to the House on February 12, 2026.  Bill HR 7528's most recent activity was Referred to the House Committee on Energy and Commerce. as of February 12, 2026

Bipartisan Support of Bill HR 7528

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 7528

Primary Policy Focus

Alternate Title(s) of Bill HR 7528

To amend section 503B of the Federal Food, Drug, and Cosmetic Act to enhance the ability of outsourcing facilities to mitigate drug shortages by allowing a short-term period to continue supplying the market after a drug is in shortage.
To amend section 503B of the Federal Food, Drug, and Cosmetic Act to enhance the ability of outsourcing facilities to mitigate drug shortages by allowing a short-term period to continue supplying the market after a drug is in shortage.

Comments